bioMérieux Expands BIOFIRE Gastrointestinal Test Panels
The company has gained regulatory clearance for two molecular panels that detect gastrointestinal pathogens from a single stool sample.
Updated on Nov. 9, 2026 in Diseases — General

bioMérieux has obtained IVDR CE marking for its BIOFIRE FILMARRAY GI1.1 Panel, which detects 22 gastrointestinal pathogens, and U.S. FDA 510(k) clearance for the smaller GI1.1 Panel Mid, which detects 11. The panels test a single stool sample and return results in about one hour.
Why it matters
Gastrointestinal infections are a major global health burden, and faster, broader molecular testing can help clinicians identify the cause of diarrheal illness more quickly. The regulatory clearances enable the panels to be marketed in the European Union and the United States.
The GI1.1 Panel covers 22 pathogens and the GI1.1 Panel Mid covers 11, with results in about one hour after roughly two minutes of hands-on setup. Diarrheal disease accounts for about 1.7 billion cases worldwide each year, but the article does not report clinical performance metrics for the panels.
The players
bioMérieux
A French multinational company that develops and manufactures diagnostic instruments and tests, including the BIOFIRE line of molecular infectious disease panels.
The details
The panels are PCR-based molecular tests run on BIOFIRE FILMARRAY 2.0 and TORCH systems, and they include a redesigned norovirus GI/GII assay and a software-based improvement for Campylobacter detection. The GI1.1 Panel will be deployed across all regions, while the Panel Mid will initially be available in the United States.
Timeline
The article does not specify a date for the regulatory clearances or the CE marking.
Diagnostic Landscape
The GI1.1 panels extend bioMérieux's BIOFIRE FILMARRAY multiplex PCR gastrointestinal testing line, which uses single-sample molecular detection in place of traditional stool culture methods. Their expanded pathogen menu and the redesigned norovirus assay place them alongside other multiplex panels competing to replace culture-based workflows.
For patients with suspected gastrointestinal infection, a single stool sample tested with these panels could return a broad pathogen result in about an hour, potentially shortening the time to a targeted treatment decision. Availability will depend on whether a clinic or laboratory has the BIOFIRE systems installed.
The takeaway
Faster multiplex stool testing can narrow the cause of diarrheal illness in hours rather than days, which matters for both individual treatment and outbreak response. Readers should check with their healthcare provider about which tests are available locally.
Further reading
For broader context on infections like those these panels detect, see Diseases — General.







